CSL growth goes on, driven by soaring Seqirus sales

18 February 2021

Australia-based biotech CSL Limited (ASX: CSL) announced its latest financial results, relating to the six-month period ending on December 31, 2020, on Wednesday.

Total revenue rose by 17% to $5.74 billion, with reported net profit after tax of $1.81 billion, up 44% at constant currencies.

"Our people and business model both demonstrated tremendous agility and resiliency in this most challenging of environments"The group’s operating segments are CSL Behring, which manufactures, markets, and develops plasma therapies, and Seqirus, which manufactures and distributes non-plasma biotherapeutic products and develops influenza-related products.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK